Impact of Genetic Polymorphism of Myeloid Differentiation Primary Response Gene 88, Enhancer of Zeste Homolog 2, and B-cell Lymphoma 2 like 11 in Patients with Diffuse Large B Cell Lymphoma Treated with Rituximab, Cyclophosphamide, Doxorubicin, Vincristin

Authors

  • Hussam Zawam Kasralainy Center of Clinical Oncology and Nuclear Medicine, Faculty of Medicine, Cairo University, Cairo, Egypt
  • Noha E. Ibrahim Department of Microbial Biotechnology, Genetic Engineering and Biotechnology Division, National Research Centre, Giza, Egypt
  • Rasha Salama Kasralainy Center of Clinical Oncology and Nuclear Medicine, Faculty of Medicine, Cairo University, Cairo, Egypt
  • Mai Samir Department of Medical Biochemistry and Molecular Biology, Faculty of Medicine, Cairo University, Cairo, Egypt
  • Walaa Abdelfattah Department of Clinical and Chemical Pathology, Faculty of Medicine, Cairo University, Cairo Egypt
  • Doaa M. El Demerdash Department of Internal Medicine, Clinical Hematology Unit, Faculty of Medicine, Cairo University, Cairo, Egypt
  • Dina Sabry Department of Medical Biochemistry and Molecular Biology, Faculty of Medicine, Cairo University, Cairo, Egypt
  • Sahar A. Tabak Department of Pathology, Faculty of Medicine, Cairo University, Cairo, Egypt
  • Rasha A. Khairy Department of Pathology, Faculty of Medicine, Cairo University, Cairo, Egypt

DOI:

https://doi.org/10.3889/oamjms.2021.5697

Keywords:

DLBCL, MYD88, EZH2, BCL211, Gene polymorphism, Cell of origin

Abstract

BACKGROUND: Despite the growing landscape of genetic drivers in Diffuse Large B-cell Lymphoma, yet their clinical implication is still unclear and R-CHOP regimen remains a “one size fits all” therapy. We aimed in this study to examine the prevalence of EZH2, BCL211 and MYD 88 genetic polymorphisms in DLBCL patients and correlate the results with various clinical and survival outcomes.

METHODS: Genotyping of MYD88 (rs387907272 T/C), EZH2 (rs3757441 C/T), and BCL2L11 (rs3789068 A/G) polymorphisms were conducted using real time polymerase chain reaction analysis in a total of 75 DLBCL patients.

RESULTS: Most of our cases carried the wild TT genotype of MYD88 gene (64%), the mutant TT genotype of EZH2 gene (52%) and the wild AA genotype of BCL2L11 gene (48%). Regarding cell of origin, Germinal Centre (GC) phenotype was present in 56% of cases while 44% expressed the Post-GC (PGC) phenotype. Poor response outcome to first line R-CHOP was significantly correlated with the mutated CC genotype of MYD 88 (p=0.02), while better response to R-CHOP was significantly associated with younger age <50 years (p <0.0001), good PS (p=0.046), normal LDH level (p=0.003), earlier stage (p <0.0001), good IPI score (p=0.009), absence of extranodal disease (p <0.0001) and absence of bulky disease (p=0.004). The median PFS and the 2 year OS were significantly higher in younger age, earlier stage, good IPI score, absence of extranodal disease, absence of bulky disease and in GC phenotype.

CONCLUSIONS: Our results emphasized that the mutated genotype of MYD 88 gene polymorphism is significantly associated with poor response to R-CHOP therapy.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

References

Phelan JD, Young RM, Webster DE, Roulland S, Wright GW, Kasbekar M, et al. A multiprotein supercomplex controlling oncogenic signalling in lymphoma. Nature. 2018;560(7718):387-91. PMid:29925955

Cunningham D, Hawkes EA, Jack A, Qian W, Smith P, Mouncey P, et al. Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: A phase 3 comparison of dose intensification with 14-day versus 21-day cycles. Lancet. 2013;381(9880):1817-26. https://doi.org/10.1016/s0140-6736(13)60313-x PMid:23615461

Alizadeh AA, Elsen MB, Davis RE, Ma CL, Lossos IS, Rosenwald A, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000;403(6769):503-11. PMid:10676951

Choi WW, Weisenburger DD, Greiner TC, Piris MA, Banham AH, Delabie J, et al. A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy. Clin Cancer Res. 2009;15(17):5494-502. https://doi.org/10.1158/1078-0432.ccr-09-0113 PMid:19706817

Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375- 90. https://doi.org/10.1182/blood-2016-01-643569 PMid:26980727

Lossos IS, Czerwinski DK, Alizadeh AA, Wechser MA, Tibshirani R, Botstein D, et al. Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes. N Engl J Med. 2004;350(18):1828-37. https://doi.org/10.1056/nejmoa032520 PMid:15115829

Schmitz R, Wright GW, Huang DW, Johnson CA, Phelan JD, Wang JQ, et al. Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma. N Engl J Med. 2018;378(15):1396-407. PMid:29641966

Mozgova I, Hennig L. The polycomb group protein regulatory network. Annu Rev Plant Biol. 2015;66:269-96. https://doi.org/10.1146/annurev-arplant-043014-115627 PMid:25621513

Sauvageau M, Sauvageau G. Polycomb group proteins: Multi-faceted regulators of somatic stem cells and cancer. Cell Stem Cell. 2010;7(3):299-313. https://doi.org/10.1016/j.stem.2010.08.002 PMid:20804967

Ling Z, You Z, Hu L, Zhang L, Wang Y, Zhang M, et al. Effects of four single nucleotide polymorphisms of EZH2 on cancer risk: A systematic review and meta-analysis. Onco Targets Ther. 2018;11:851-65. https://doi.org/10.2147/ott.s158173 PMid:29497317

Hata AN, Engelman JA, Faber AC. The BCL2 Family: Key Mediators of the Apoptotic Response to Targeted Anticancer Therapeutics. Cancer Discov. 2015;5(5):475-87. https://doi.org/10.1158/2159-8290.cd-15-0011 PMid:25895919

Jeelall YS, Horikawa K. Oncogenic MYD88 mutation drives Toll pathway to lymphoma. Immunol Cell Biol. 2011;89(6):659-60. https://doi.org/10.1038/icb.2011.31 PMid:21519346

Lee JH, Jeong H, Choi JW, Oh HE, Kim YS. Clinicopathologic significance of MYD88 L265P mutation in diffuse large B-cell lymphoma: A meta-analysis. Sci Rep. 2017;7(1):1785. https://doi.org/10.1038/s41598-017-01998-5 PMid:28496180

Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Delabie J, Ott G, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004;103(1):275-82. https://doi.org/10.1182/blood-2003-05-1545 PMid:14504078

Ngo VN, Young RM, Schmitz R, Jhavar S, Xiao W, Lim K, et al. Oncogenically active MYD88 mutations in human lymphoma. Nature. 2011;470(7332):115-9. PMid:21179087

Morin RD, Johnson NA, Severson TM, Mungall AJ, An J, Goya R, et al. Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nat Genet. 2010;42(2):181-5. https://doi.org/10.3410/f.2738956.2402054 PMid:20081860

Schuetz JM, Johnson NA, Morin RD, Scott DW, Tan K, Ben-Nierah S, et al. BCL2 mutations in diffuse large B-cell lymphoma. Leukemia. 2012;26(6):1383-90. https://doi.org/10.1038/leu.2011.378 PMid:22189900

Saito M, Novak U, Piovan E, Basso K, Sumazin P, Schneider C, et al. BCL6 suppression of BCL2 via Miz1 and its disruption in diffuse large B cell lymphoma. Proc Natl Acad Sci U S A. 2009;106(27):11294-9. https://doi.org/10.1073/pnas.0903854106 PMid:19549844

Ziepert M, Hasenclever D, Kuhnt E, Glass B, Schmitz N, Pfreundschuh M, et al. Standard international prognostic index remains a valid predictor of outcome for patients with aggressive CD20+ B-cell lymphoma in the rituximab era. J Clin Oncol. 2010;28(14):2373-80. https://doi.org/10.1200/jco.2009.26.2493 PMid:20385988

Fernández-Rodríguez C, Bellosillo B, García-García M, Sánchez-González B, Gimeno E, Vela MC, et al. MYD88 (L265P) mutation is an independent prognostic factor for outcome in patients with diffuse large B-cell lymphoma. Leukemia. 2014;28(10):2104-6. https://doi.org/10.1038/leu.2014.184 PMid:24903481

Yu X, Li W, Deng Q, Li L, Hsi ED, Young KH, et al. MYD88 L265P mutation in lymphoid malignancies. Cancer Res. 2018;78(10):2457-62. https://doi.org/10.1158/0008-5472.can-18-0215 PMid:29703722

Wilson WH, Young RM, Schmitz R, Yang Y, Pittaluga S, Wright G, et al. Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma. Nat Med. 2015;21(8):922-6. PMid:26193343

Facciotto C, Casado J. Epigenetic inhibitors sensitize DLBCL cells to rituximab and doxorubicin. Αγαη. 2019;8(5):55. https://doi.org/10.1101/538199

Deng Y, Chen X, Huang C, Chen G, Chen F, Lu J, et al. EZH2/ Bcl-2 coexpression predicts worse survival in diffuse large B-cell lymphomas and demonstrates poor efficacy to rituximab in localized lesions. J Cancer. 2019;10(9):2006-17. https://doi.org/10.7150/jca.29807 PMid:31205561

Cummin T, Araf S, Du MQ, Barrans S, Bentley MA, Clipson A, et al. Prognostic significance and correlation to gene expression profile of EZH2 mutations in diffuse large B-cell lymphoma (DLBL) in 2 large prospective studies. Hematol Oncol. 2017;35:158-9. https://doi.org/10.1002/hon.2438_13

Downloads

Published

2021-02-21

How to Cite

1.
Zawam H, Ibrahim NE, Salama R, Samir M, Abdelfattah W, El Demerdash DM, Sabry D, Tabak SA, Khairy RA. Impact of Genetic Polymorphism of Myeloid Differentiation Primary Response Gene 88, Enhancer of Zeste Homolog 2, and B-cell Lymphoma 2 like 11 in Patients with Diffuse Large B Cell Lymphoma Treated with Rituximab, Cyclophosphamide, Doxorubicin, Vincristin. Open Access Maced J Med Sci [Internet]. 2021 Feb. 21 [cited 2021 May 9];9(A):98-105. Available from: https://oamjms.eu/index.php/mjms/article/view/5697